Type I interferon induces cancer stem cells-mediated chemotherapy resistance. uri icon

Overview

abstract

  • In a recent study in Nature Immunology, Musella et al. demonstrate that suboptimal type I interferon (IFN-I) signaling in tumors undergoing immunogenic cell death (ICD) facilitates the accumulation of cancer stem cells (CSCs) by triggering the epigenetic regulator lysine demethylase 1B (KDM1B). KDM1B stands out as a promising target for the development of novel strategies to improve anti-cancer responses driven by ICD.

publication date

  • September 22, 2022

Research

keywords

  • Interferon Type I
  • Neoplasms

Identity

PubMed Central ID

  • PMC9518997

Scopus Document Identifier

  • 85138690294

Digital Object Identifier (DOI)

  • 10.1080/2162402X.2019.1655964

PubMed ID

  • 36185803

Additional Document Info

volume

  • 11

issue

  • 1